Application of 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Author is Gusho, Charles A.; Weiss, Mia C.; Lee, Linus; Gitelis, Steven; Blank, Alan T.; Wang, Dian; Batus, Marta.
Sarcomas are a rare and heterogeneous tumor group composed of a variety of histol. subtypes. Targeted next-generation sequencing (NGS) of bone and soft tissue sarcomas is a nascent field with limited evidence for its use within clin. practice. Therefore, further research is needed to validate NGS in sarcoma and assess the clin. utility of these techniques with the hope of improving treatment options. Comprehensive mol. profiling with NGS was performed on 136 tumors (116 soft tissue, 20 bone) using two com. vendors. Patient records were retrospectively reviewed, and the clin. impact of NGS-related findings were qual. analyzed to determine actionable mutations and number of changes in treatment. The median age was 55.0 years (IQR 42-67 years), and most patients were non-metastatic at presentation (80.9%, n = 110). Prior to performing NGS, 72.1% (n = 98) were treated with a mean 1.1 ± 1.2 lines of systemic chemotherapy. NGS identified 341 putative alterations with at least one mutation present in 89.7% (n = 122) of samples. In a subset of 111 patients with available TMB data, 78.7% (n = 107) had a low (<6 m/Mb) mutational burden. Among all 136 cases, 47.1% (n = 64) contained clin. actionable alterations, and 12 patients had a change in medical treatment based on NGS. Those who underwent a treatment change all had metastatic or recurrent disease; three of these patients experienced a clin. benefit. Most bone and soft tissue sarcomas harbor at least one genetic alteration, and it appears a sizeable number of tumors contain mutations that are clin. actionable. While a change in treatment based off NGS-related findings occurred in 12 cases, three patients experienced a clin. benefit. Our data provide further proof-of-concept for NGS in sarcoma and suggest a clin. benefit may be observed in select patients. In some applications, this compound(41575-94-4)Application of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics